CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) today announced that the Paul-Ehrlich-Institut (PEI), the agency that regulates blood components in Germany, has approved the sale of platelets treated with the INTERCEPT Blood System by a German blood center located in the University Hospital Schleswig-Holstein, Campus Lübeck. Applications are in progress for other German blood centers for similar marketing approvals.
